{"doi":"10.2217/fon-2020-0504","title":"Current Trends in the Treatment of HR+/HER2+ Breast Cancer","abstract":null,"journal":"Future Oncology","year":2021,"id":608126,"datarank":0.6090664515819629,"base_score":4.060443010546419,"endowment":4.060443010546419,"self_citation_contribution":0.6090664515819629,"citation_network_contribution":0.0,"self_endowment_contribution":0.6090664515819629,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":57,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1561706,"name":"Carlos Martínez-Pérez","orcid":"0000-0002-4846-2832","position":1,"is_corresponding":false},{"id":1561708,"name":"James Meehan","orcid":null,"position":2,"is_corresponding":false},{"id":494709,"name":"Mark Gray","orcid":null,"position":3,"is_corresponding":false},{"id":1561714,"name":"Victoria Webber","orcid":null,"position":4,"is_corresponding":false},{"id":1518027,"name":"J Michael Dixon","orcid":null,"position":5,"is_corresponding":false},{"id":1561718,"name":"Arran K Turnbull","orcid":"0000-0002-2287-0889","position":6,"is_corresponding":false},{"id":1561704,"name":"Charlene Kay","orcid":"0000-0002-7454-9528","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Current Trends in the Treatment of HR+/HER2+ Breast Cancer","abstract":"Treatment for HR+/HER2+ patients has been debated, as some tumors within this luminal HER2+ subtype behave like luminal A cancers, whereas others behave like non-luminal HER2+ breast cancers. Recent research and clinical trials have revealed that a combination of hormone and targeted anti-HER2 approaches without chemotherapy provides long-term disease control for at least some HR+/HER2+ patients. Novel anti-HER2 therapies, including neratinib and trastuzumab emtansine, and new agents that are effective in HR+ cancers, including the next generation of oral selective estrogen receptor downregulators/degraders and CDK4/6 inhibitors such as palbociclib, are now being evaluated in combination. This review discusses current trials and results from previous studies that will provide the basis for current recommendations on how to treat newly diagnosed patients with HR+/HER2+ disease.","is_dataset_classified":null,"base_score":4.060443010546419,"endowment":4.060443010546419,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33726508","pmcid":null,"openalex_id":"https://openalex.org/W3136150824","authors":[],"funders":[],"total_grants":0,"fwci":4.8247,"citation_percentile":0.96218505,"influential_citations":0,"citation_trend":[{"year":2021,"count":3},{"year":2022,"count":4},{"year":2023,"count":20},{"year":2024,"count":10},{"year":2025,"count":16},{"year":2026,"count":4}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://doi.org/10.2217/fon-2020-0504","host_type":"journal"},{"url":"https://doi.org/10.2217/fon-2020-0504","host_type":"publisher"},{"url":"https://www.tandfonline.com/doi/pdf/10.2217/fon-2020-0504","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33726508","host_type":"repository"},{"url":"https://www.research.ed.ac.uk/en/publications/111a77a1-28cf-4fd4-ab38-f52f02555cc8","host_type":"repository"},{"url":"http://www.scopus.com/inward/record.url?scp=85103929869&partnerID=8YFLogxK","host_type":"repository"},{"url":"https://www.research.ed.ac.uk/files/252557484/Current_trends_in_the_treatment_of_hormone_receptor_positive_HER2_positive_breast_cancer.pdf","host_type":"repository"}],"fields_of_study":["Advanced Breast Cancer Therapies","HER2/EGFR in Cancer Research","Chronic Lymphocytic Leukemia Research"],"mesh_terms":["Trastuzumab","Progression-Free Survival","Antineoplastic Combined Chemotherapy Protocols","Breast","Breast Neoplasms","Camptothecin","Clinical Trials as Topic","Female","Humans","Mastectomy","Piperazines","Pyridines","Quinolines","Receptors, Estrogen","Receptors, Progesterone","Chemotherapy, Adjuvant","Erb-b2 Receptor Tyrosine Kinases","Receptor, ErbB-2","Immunoconjugates","Neoadjuvant Therapy","Protein Kinase Inhibitors","Molecular Targeted Therapy","Estrogen Receptor Antagonists"],"keywords":["Medicine","Palbociclib","Neratinib","Trastuzumab","Oncology","Trastuzumab emtansine","Internal medicine","Breast cancer","Lapatinib","Metastatic breast cancer","Disease","Clinical trial","Pertuzumab","Cancer","Chemotherapy","Combination treatment","Clinical Trials","Emerging Therapeutics","Her2+","Triple-positive Breast Cancer","Luminal Her2","Hr+/her2+"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T07:32:41.254621Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}